Switzerland / Lonza Goes Big with Investments in Biologics, ADCs & Vaccines Manufacturing
In the last month alone, CDMO giant Lonza has announced three major upgrades to its manufacturing footprint in…
Top Stories
APAC / How Precision Medicine is Transforming the Oncology Landscape
Asia-Pacific, as home to 50 percent of the world’s new cancer cases each year and with deaths caused by cancer expected to increase by 36 percent by 2030, has a…
Canada / Top 10 Pharma Companies 2020 Ranking
The Top 10 companies in the Canadian pharma market for 2020, ranked by revenues in USD billions. J&J takes the…
China / EpimAb Looks to 2022 IPO & Global Leadership in Bispecific Antibodies
Hot on the heels of a USD 120 million fundraising round, Shanghai-based EpimAb Biotherapeutics is now looking…
Argentina / Politics and Pharma M&A
The COVID-19 pandemic has caused economic and social disruption and affected the behaviour of both consumers and…
Moderna / Bullish Bancel “Not Losing Sleep” over COVID-19 Vaccine IP Waiver, Looking to mRNA’s Future in Rare Diseases & Oncology
The day the Biden administration announced its support for the waiver of IP rights for COVID-19 vaccines,…
Turkey / Koçak Farma & The Push for Homegrown COVID-19 Vaccines
As the international community continues its quest to vaccinate the global population against COVID-19, shortages…
In Conversation
Sizhen Wang – CEO & Co-Founder, Genetron Health
Genetron Health is a publicly-traded China-based precision oncology company, covering the “full-cycle” of cancer care, from early screening, diagnosis, and treatment recommendations to continuous monitoring care. CEO and Co-Founder Sizhen Wang explains how the company obtained US FDA Breakthrough Device Designation, analyzes the Chinese biotech sector, and highlights their objective to transform cancer from a terminal disease to a non-life-threatening…
Latest Reports
Focus on Switzerland
MSD Switzerland AVP on Recent Zurich R&D Investment
In February 2020, US giant MSD announced the launch of a new site in Zurich…
Switzerland’s Quest for Alternatives to Animal Testing of…
Animal testing for medicinal purposes is back under the spotlight in Switzerland…
Lonza Goes Big with Swiss Investments in Biologics, ADCs…
In the last month alone, CDMO giant Lonza has announced three major upgrades to…
Ichnos CEO on Glenmark Legacy, Biotech Transformation &…
After an illustrious career in oncology R&D, contributing greatly to the…
Read more: Switzerland >>
Focus on Europe
UK Pharma News: Fastest Growing Private Pharmacos; GSK…
The latest UK pharma news, including how new investment in GSK stands to reshape…
Spanish Pharma News: Market Growth; Esteve’s US Expansion;…
The latest from Spanish pharma, including the acquisition of PTS by a private…
Vaccine Wars: What the EU/AstraZeneca Row Shows Us About…
Stuart Evans, partner at law firm BLM and specialist in commercial disputes and…
MSD Switzerland AVP on Recent Zurich R&D Investment
In February 2020, US giant MSD announced the launch of a new site in Zurich…
Read more: Europe >>
Focus on Vaccines
Turkey: Koçak Farma & The Push for Homegrown COVID-19…
As the international community continues its quest to vaccinate the global…
Innovative Pharma Doubles Down on IP with New Pact
On World Intellectual Property (IP) Day 2021, the innovative biopharmaceutical…
Moderna: Bullish Bancel “Not Losing Sleep” over COVID-19…
The day the Biden administration announced its support for the waiver of IP…
Vaccine Wars: What the EU/AstraZeneca Row Shows Us About…
Stuart Evans, partner at law firm BLM and specialist in commercial disputes and…
Read more: Vaccines >>
Focus on Singapore
The Challenges of Regulatory Convergence in APAC Medtech
Regulatory harmonisation for medical devices between countries in Asia-Pacific…
APAC: How Precision Medicine is Transforming the Oncology…
Asia-Pacific, as home to 50 percent of the world’s new cancer cases each year…
Medtech’s Post-COVID Paradigm in APAC
At USD 150 billion, Asia-Pacific is home to the world’s second largest medtech…
Singapore: Finding the Right Pharma Talent Post-COVID
Singapore – despite its modest USD 1.22 billion domestic market – has long…
Read more: Singapore >>
Focus on USA
USA: 2 Things the Biden Administration can do Now to Lower…
PhRMA’s Stephen J. Ubl outlines two ways in which the new US presidency can…
US U-Turn as Biden Pledges Support for Waiver on COVID-19…
In a shock move, Joe Biden’s administration looks set to support a waiver on…
Novavax: From No-Hoper to COVID-19 Vaccine Saviour?
From almost being de-listed by the NASDAQ stock index in 2018 due to poor…
NORD Chief Strategy Officer on Health Equity’s Vital…
With Rare Disease Day coming up on February 28th, one of the leading…
Read more: USA >>
Focus on China
Public Insurance Coverage for Rare Disease Patients in…
Kevin Rufang Huang, president and founder of the Chinese Organization for Rare…
Top 10 Chinese Pharma Companies 2020
The Top 10 Chinese pharma companies for 2020 ranked by overall revenues. Taken…
China: EpimAb Looks to 2022 IPO & Global Leadership in…
Hot on the heels of a USD 120 million fundraising round, Shanghai-based EpimAb…
China Pharma News: Antitrust Threat to Pharma; June BioNTech…
The latest China pharma news, including the upcoming first domestic approval for…
Read more: China >>
Focus on MEA
5 Things to Know about Saudi Arabian Pharma
A rundown of five things to know about the USD 8.2 billion Saudi pharma market,…
MEA: Iran looks to Cuba for COVID-19 Vaccine; Israel Leads…
The latest COVID-19 vaccine news from the Middle East & Africa (MEA) region,…
MENA Pharma News: Egypt Opens ‘Pharma City’;…
The latest Middle East and North Africa (MENA) pharma, including Egypt’s…
MEA: Pfizer’s Saudi Transformation; Urgent Call for Arab…
The latest news from Middle East & North African pharma, including…